Pediatric Epilepsy Therapeutics Markets, 2019-2023 - The Global Industry is Dominated by Eisai, GlaxoSmithKline, GW Pharmaceuticals, Pfizer, and UCB
Dublin, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Pediatric Epilepsy Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.
The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures.
Increasing demand for second and third-generation AEDs
The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.
Adverse side effects and increasing social stigma
The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.
Competitive Landscape
With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.
Key Players
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Second-generation anti-epileptics - Market size and forecast 2018-2023
- Third-generation anti-epileptics - Market size and forecast 2018-2023
- First-generation anti-epileptics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
For more information about this report visit https://www.researchandmarkets.com/research/tmlk9j/pediatric?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Central Nervous System Drugs , Pediatrics
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.